Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment
| Autor: | Jean-Michel Dayer, François Chasset, Carlo Chizzolini |
|---|---|
| Přispěvatelé: | Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Geneva University Hospital (HUG) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
keratinocytes polymorphonuclear neutrophils (PMN) Efferent Individualized treatment RM1-950 Review behavioral disciplines and activities [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity Disease activity 03 medical and health sciences 0302 clinical medicine Immune system autoantibody (autoAb) Afferent mental disorders interferon-stimulated genes (ISGs) Medicine genetic polymorphism Pharmacology (medical) systemic lupus erythematosus (SLE) 030203 arthritis & rheumatology Pharmacology business.industry Autoantibody interferon [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy Precision medicine 3. Good health 030104 developmental biology [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology Immunology behavior and behavior mechanisms Therapeutics. Pharmacology business systemic autoimmune diseases (SADs) psychological phenomena and processes |
| Zdroj: | Frontiers in Pharmacology Frontiers in Pharmacology, Frontiers, 2021, 12, pp.633821. ⟨10.3389/fphar.2021.633821⟩ Frontiers in Pharmacology, Vol 12 (2021) |
| ISSN: | 1663-9812 |
| DOI: | 10.3389/fphar.2021.633821⟩ |
| Popis: | International audience; A sustained increase in type I interferon (IFN-I) may accompany clinical manifestations and disease activity in systemic autoimmune diseases (SADs). Despite the very frequent presence of IFN-I in SADs, clinical manifestations are extremely varied between and within SADs. The present short review will address the following key questions associated with high IFN-I in SADs in the perspective of precision medicine. 1) What are the mechanisms leading to high IFN-I? 2) What are the predisposing conditions favoring high IFN-I production? 3) What is the role of IFN-I in the development of distinct clinical manifestations within SADs? 4) Would therapeutic strategies targeting IFN-I be helpful in controlling or even preventing SADs? In answering these questions, we will underlie areas of incertitude and the intertwined role of autoantibodies, immune complexes, and neutrophils. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|